宫颈癌中COX-2与p53、E-cadherin蛋白表达的关系

目的　探讨宫颈癌组织中环氧合酶 2 (COX 2 )的表达与 p5 3、E cadherin蛋白表达的关系。 方法　采用免疫组织化学S P法检测 4 1例宫颈癌和 10例正常宫颈上皮组织中COX 2、p5 3、E cadherin蛋白的表达水平。结果　宫颈癌组织中COX 2、p5 3表达水平明显高于正常宫颈上皮 (P <0 .0 1) ,而E cadherin蛋白的表达水平明显低于正常宫颈上皮 (P <0 .0 1) ;COX 2的高表达与宫颈癌淋巴结转移和浸润深度有关 (P <0 .0 5 ) ,与患者年龄、临床分期、组织学类型、分化程度无关 (P >0 0 5 ) ;COX 2表达阳性组 p5 3的表达水平明显高于COX 2表达阴性组 (P <0 0 5 ) ,COX 2表达阳性组的E cadherin蛋白的表达水平则低于相对应阴性组 ,差异有显著性 (P <0 0 5 )。结论　在宫颈癌的发生发展中COX 2、p5 3、E cadherin可能起重要作用。COX 2通过使抑癌基因p5 3失活 ,降低细胞黏附分子E cadherin的水平促进宫颈癌的发生。     

卵巢上皮性癌组织中轴突导向蛋白4D的表达与微血管密度的关系

卵巢上皮性癌(卵巢癌)的病死率居妇科恶性肿瘤的首位,总的5年生存率仅为30%左右,其原因与癌组织血管丰富,易发生转移导致患者预后不良密切相关[1].卵巢癌组织中的微血管密度(microvessel density,MVD)是评价血管生成的重要指标[2].     

沉默轴突导向蛋白4D基因对卵巢癌SKOV3细胞恶性生物学行为的影响

Objective To observe the effect of DNA Sema4D gene silencing by RNA interfering on the proliferation, migration and invasion of human ovarian cancer SKOV3 cells, and to study the effect of pshRNASema4D on the growth of SKOV3 cells in transplanted tumor in nude nice. Methods Recombinant plasmid pshRNASema4D-A, B and C were respectively transfected into SKOV3 cells by lipofetamine 2000, while cells transfected by plasmid vector pcDNA3.1 and cells untreated as control groups. RT-PCR was adopted to select the recombinant plasmid which showed the most optimal inhibition effect. RT-PCR and Western blotwere used to detected the mRNA and protein expression of Sema4D in SKOV3 cells tranfected for 24, 48 and 72 hours. MTT assay was used to investigate the proliferation of the SKOV3 cells after trasnsfection. Transwell cell migration and invasion assays were used to investigate the migration and invasion abilities of the SK0V3 cells after trasnsfection. Human ovarian cancer model was established in nude mice, and the nude mice were treated with pshRNASema4D-B once every 3 days for 3 weeks. The bulk of the transplanted tumor was measured. Results Three Sema4D-targeted short hairpin RNA (shRNA) A, B and C were successfully inserted into the plasmid vector pshRNA, and the coding sequences of the obtained shRNA were consistent with the designed fragment. The results indicated that both recombinant plasmid pshRNASema4D-A and B could effectively knock down the expression of Sema4D gene in human ovarian cancer cells, of which pshRNASema4D-B was the better choice, while no effect of pshRNASema4D-C was seen. RT-PCR results showed that the relative mRNA expression of Sema4D gene in SKOV3 cells transfected with pshRNA-Sema4D for 24, 48 and 72 hours were 0. 401 ±0.051, 0. 120 ±0.035 and 0.014 ±0. 015, respectively, which were significantly lower than that in SKOV3 cells transfected by empty vector and non-transfected cells at 72 hours after transfection. (0.521 ±0.019, 0.536 ±0.040,respectively, P<0.05). The Westen blot analysis manifested that the relative expression of Sema4D protein of SKOV3 cells transfected by pshRNASema4D for 24, 48 and 72 hours were 0. 196 ± 0. 023, 0. 074 ± 0. 015 and 0. 040 ± 0.014, respectively, which were significantly lower than that in SKOV3 cells transfected by empty vector and non-transfected cells at 72 hours after transfection. (0. 275 ± 0. 009, 0. 282 ± 0. 015, respectively, P < 0. 05 ). Comparing with the empty vector-transfected and non-transfected cells, the proliferation, invasion and migration ability of SKOV3 cells transfected with pshRNA-Sema4D were obviously weakened. The pshRNASema4D-B significantly suppressed the growth of the SKOV3 cells-transplanted tumors in nude mice, and the IR( inhibitory rate ) of pshRNASema4D-B group was ( 61.0 ± 3.3 ) % ( P < 0.05). Conclusions Sema4D can be successfully silenced by RNA interfering in human ovarian cancer SKOV3 cells. Downregulation of Sema4D can inhibit the proliferation, migration and invasion of ovarian cancer cells. The pshRNASema4D can significantly suppress the growth in transplanted tumor of human ovary cancer in nude mice. Sema4D may become a candidate gene of gene therapy of human ovarian cancer.     

PI3K/AKT特异性抑制剂LY294002对卵巢癌化疗增敏作用的研究

目的:探讨磷脂酰肌醇-3-激酶(PI3K)抑制剂LY294002对卵巢癌化疗效果的影响.方法:将LY294002单独或与顺铂、紫杉醇联合作用于卵巢癌A2780、SKOV3细胞.MTT法检测DDP、顺铂单独或联合LY294002处理后对A2780、SKOV3细胞的抑制率;采用流式细胞技术检测药物单独或联合作用对A2780和SKOV3细胞凋亡的影响;应用Western blot检测A2780和SKOV3细胞中AKT及磷酸化AKT(p-AKT)蛋白表达的变化.结果:联合应用LY294002能够显著提高DDP、paclitaxel对A2780和SKOV3细胞抑制率;LY294002与DDP、paclitaxel的协同治疗指数小于1,二者起协同治疗作用;联合LY294002能够增加A2780和SKOV3细胞的凋亡水平.LY294002干预组与对照组相比p-AKT蛋白的表达降低,差异有统计学意义(P<0.01).结论:LY294002能够有效提高卵巢癌A2780和SKOV3细胞对化疗药物DDP和paclitaxel的敏感性,抑制PI3K/AKT介导的信号传导通路,可明显提高卵巢癌细胞的化疗效果.     

HIF-1α、VEGF和Sema4D蛋白在卵巢癌组织中的表达及其临床意义

实体肿瘤在发展过程中,因体积增大、血液供应不足而出现缺氧,缺氧又通过关键的转录因子——缺氧诱导因子(hypoxia inducible factor,HIF)使肿瘤血管增生、转移等恶性行为更加明显[1].HIF-1α在恶性肿瘤发生、发展中所发挥的作用主要与其调节的下游基因,如血管内皮生长因子(VEGF)等有关[2].研究证实,HIF-1α通过上调轴突导向蛋白(semaphorin,Sema;又名:信号素)Ⅳ亚族中的重要成员—Sema4D的表达,增强内皮细胞趋化运动,介导肿瘤血管的发生,从而促进恶性肿瘤远处转移[3].Sema4D是近来越来越受到关注的参与肿瘤血管发生的重要蛋白分子[4].研究发现,卵巢癌组织中Sema4D的阳性表达率明显高于良性卵巢肿瘤和正常卵巢组织[5].为进一步研究卵巢癌发生、发展的相关因素,本研究通过免疫组化方法探讨HIF-1α、VEFG和Sema4D在卵巢癌组织中的表达及3者之间的关系,并分析其临床意义.